
    
      This study is randomized double blind placebo controlled. Patients with acute coronary
      syndrome taking standard therapy including atorvastatin 40 mg/day were randomized into 2
      groups: group 1 takes Ropren 8 drops 3 times per day for 3 week, then 5 drops 3 times per day
      for 5 weeks; group 2 take placebo in the same dose regimen. The hepatoprotective,
      hypolipidemic, antiinflammatory, cognitive, antidepression functions evaluates after one and
      two - month therapy
    
  